The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...
Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...
The FDA has approved the sBLA of Eisai and Biogen's LEQEMBI for maintenance dosing indicated for the early stages of ...
Merck and Eisai said on Friday a combination of their cancer therapies failed to extend the lives of patients with a type of ...
The Japanese and American based pharma companies announced a win for their Alzheimer’s treatment, which has faced some negative backlash over the last year.
Eisai and Biogen have secured US Food and Drug Administration approval for a once-monthly intravenous maintenance dosing ...
Japanese pharmaceutical company Eisai Co. and U.S. firm Biogen Inc. said Monday that a jointly developed Alzheimer's drug has ...
The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...
Biogen and Eisai have won Food and Drug Administration approval of an intravenous maintenance dosing of their Leqembi drug for early Alzheimer's disease. The companies late Sunday said the FDA ...
Biogen and Eisai’s Alzheimer’s disease (AD) drug Leqembi (lecanemab-irmb) has been approved by the US Food and Drug ...
Results have been announced from a Phase III trial of Merck & Co’s anti-PD-1 therapy Keytruda (pembrolizumab) plus Lenvima ...
MSD and Eisai’s trial saw mixed success with its two primary endpoints, seeing success in progression-free survival, but ...